A phase I, double-blind, placebo-controlled, single-dose, dose-escalation study of the safety, pharmacokinetics, and preliminary efficacy of XOMA 052 in subjects with type 2 diabetes mellitus.

Trial Profile

A phase I, double-blind, placebo-controlled, single-dose, dose-escalation study of the safety, pharmacokinetics, and preliminary efficacy of XOMA 052 in subjects with type 2 diabetes mellitus.

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Sep 2009

At a glance

  • Drugs Gevokizumab (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors XOMA
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 30 Sep 2009 Status changed from active, no longer recruiting to completed. Phase I trials of XOMA 052 are complete according to a XOMA media release.
    • 14 Jul 2009 Interim results were reported in a Xoma media release; Xoma announced positive results from single and multiple dose subcutaneous arms of the trial; Placebo patients from both US and Sweden Phase I trials included.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top